SCHEMBL1725828

SCHEMBL1725828

N=C(NO)c1cnc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
S1PR2 O95136 1/20 0.39
S1PR4 O95977 1/20 0.39
S1PR3 Q99500 1/20 0.39
S1PR5 Q9H228 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1727324 0.83 HDAC3 (0.33) KMT2AHDAC3HDAC1HDAC2HDAC6
SCHEMBL15891073 0.81 IDO1 (0.35) TDP1HDAC3HDAC1HDAC2HDAC6
SCHEMBL1425157 0.81 KMT2A (0.35) KMT2AMEN1RXFP1HDAC3HDAC1
SCHEMBL15891096 0.81 CYP2D6 (0.35) KMT2AHDAC3HDAC1HDAC2HDAC6
SCHEMBL7832453 0.78 KMT2A (0.31) KMT2AHDAC3HDAC1HDAC2HDAC6
SCHEMBL16000808 0.77 KMT2A (0.54) KMT2AALDH1A1MEN1KDM4ESMN1; SMN2
SCHEMBL1728982 0.74 LMNA (0.35) KMT2AALDH1A1MEN1KDM4ETDP1
SCHEMBL1965619 0.74 RORC (0.37) S1PR3S1PR5
SCHEMBL8121970 0.71 TTR (0.46) KMT2AALDH1A1MEN1KDM4ESMN1; SMN2
SCHEMBL25199069 0.71 HCAR2 (0.52) S1PR4S1PR3SLC6A3KCNH2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2709609-B1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO (JP) 2017-10-04 EP disclosed
US-9156830-B2 Heterocyclic compounds SHIONOGI & CO., LTD. (JP) 2015-10-13 US disclosed
US-20140249159-A1 HETEROCYCLIC COMPOUNDS PURDUE PHARMA L.P. 2014-09-04 US disclosed
US-8791142-B2 Oxazole pyridine derivatives useful as S1P1 receptor agonists MERCK SERONO S.A. (CH) 2014-07-29 US disclosed
EP-2709609-A1 HETEROCYCLIC COMPOUNDS Shionogi & Co., Ltd. (JP) 2014-03-26 EP disclosed
WO-2012158844-A1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO., LTD. (JP) 2012-11-22 WO disclosed
EP-2403849-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS Merck Serono S.A. (CH) 2012-01-11 EP disclosed
US-20110306636-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO SA (CH) 2011-12-15 US disclosed
WO-2010100142-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS MERCK SERONO S.A. (CH) 2010-09-10 WO disclosed
EP-1114045-A1 2-METHOXYIMINO-2-(PYRIDINYLOXYMETHYL)PHENYL ACETAMIDES WITH 5 MEMBERED HETEROCYCLIC RINGS ON THE PYRIDINE RING AS FUNGICIDES Dow AgroSciences LLC (US) 2001-07-11 EP disclosed
US-6133294-A APPLYING AS FUNGICIDES DOW AGROSCIENCES LLC 2000-10-17 US disclosed
WO-2000015637-A1 2-METHOXYIMINO -2-(PYRIDINYLOXYMETHYL) PHENYL ACETAMIDES WITH 5 MEMBERED HETEROCYCLIC RINGS ON THE PYRIDINE RING AS FUNGICIDES DOW AGROSCIENCES LLC (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249159-A1 HETEROCYCLIC COMPOUNDS HRH2, UGT1A3, UGT1A1 KMT2A 3048/4885S1PR2 2884/4885S1PR4 4019/4885
US-20110306636-A1 OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS S1PR1, S1PR3, S1PR5 KMT2A 3880/4885S1PR2 4/4885S1PR4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.